Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.